YL 18319
Alternative Names: YL-18319Latest Information Update: 28 Feb 2025
At a glance
- Originator Shanghai Yingli Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly ADP ribose glycohydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Oct 2024 Preclinical trials in Cancer in China (PO)
- 23 Oct 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 23 Oct 2024 Shanghai Yingli Pharmaceutical plans a phase I trial for Cancer (Late-stage diseases) (PO)